The role of pharmacotherapy in the treatment of chronic thromboembolic pulmonary hypertension (RCD code: II-1A.5)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2015, Vol 2, Issue 2
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a debilitating disease caused by chronic obstruction of major pulmonary arteries. The median age of patients at diagnosis of CTEPH is 63 years and both genders are equally affected. The symptoms are usually nonspecific, particularly in the early stages of the disease, which significantly delays the diagnosis. All patients with pulmonary hypertension (PH) of the unknown aetiology should be diagnosed for CTEPH, even without the information on pulmonary embolism in the medical history. Ventilation-perfusion scintigraphy of the lungs has the highest sensitivity in the diagnosis of CTEPH. A positive result of scintigraphy suggestive of CTEPH is not enough to diagnose the disease. Right heart catheterization and angiography of the pulmonary arteries definitively confirm the diagnosis. All patients with CTEPH should receive chronic oral anticoagulation using generally vitamin K antagonists (warfarin, acenocumarol). Pulmonary endarterectomy (PEA) is the only effective treatment for eliminating the cause of the disease. However, not all patients can be referred for pulmonary endarterectomy surgery. According to data from the European CTEPH Registry of the years 2007-2009, over 40% of patients is not subjected to the operation mainly due to the distal location of thromboembolic changes. Currently, riociguat is the only approved therapeutic agent for the pharmacological treatment of inoperable/persistent CTEPH. In some cases, Off-lebel use of drugs approved for PAH may be considered in symptomatic patients with inoperable CTEPH/persistent PH after PEA. Recent advances in balloon pulmonary angioplasty make it a promising therapeutic alternative for selected patients with non-operable CTEPH. JRCD 2015; 2 (2): 4–8
Authors and Affiliations
Barbara Widlińska, Grzegorz Kopeć, Piotr Podolec
Keywords
Related Articles
- EP ID EP245454
- DOI 10.20418/jrcd.vol2no2.164
- Views 87
- Downloads 0
Common problems in rare congenital heart diseases
Congenital heart disease (CHD) is the most common developmental anomaly and is found in about 1% of all live-born children.Recent progress in cardiac surgery and pediatric cardiology hasresulted in large numbers of adult...
Venous system anomaly as a reason for misplacement of pacemaker lead (RCD code: IV1C.1)
We present a case of a 45-year old patient with history of surgical ASD II closure and pacemaker implantation who was only recently diagnosed with lead mispalcement due to anomalous venous return.
“A rare day to put rare diseases in the spotlight!” “With research possibilities are limitless”
Just few days ago, on 28th February, the tenth edition of Rare Disease Day was launched by EURORDIS and its Council for National Alliances to attract thousands people all over the world to come together to advocate for m...
Hemangioma of the left ventricle (RCD code: VI-1B.4)
Cardiac tumors are quite rare, and differential diagnosis of them is challenging.We present the case report of a young man complaining on non specific chest pain who was reported to Cardiology Ward due to suspicion of th...
A 35-year old man with dyspnea on exertion, history of acute pulmonary embolism and ischaemic stroke
We present a case of a 35-year old man with a history of an acute pulmonary embolism and ischaemic stroke, who after several weeks of adequate antithrombotic treatment experienced functional deterioration with severe dys...